Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu HengRui Medicine Co., Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a pathologically or cytologically documented advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and colorectal cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.
At least one evaluable or measurable lesion should be present and identified according to Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1.
Has an ECOG PS 0-1.
Has a life expectancy of ≥ 3 months.
Has adequate organ function
You may not be if
Has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI-CTCAE version 5.0 grade ≤ 1.
Has received HER2 antibody drug conjugates,.
Central nervous system metastasis or meningeal metastasis with clinical symptoms
Has active infection requiring systemic treatment.
Clareo Health | A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
